MYCN and triple-negative breast carcinoma: Bromodomain and extra-terminal domain (BET) protein inhibitor JQ1 has recently been reported to improve the survival in pre-clinical neuroblastoma mouse models, impact several cellular pathways, including MYCN expression [22], and impair hypoxic responses in triple-negative breast cancer [24].